Innovation Pharmaceuticals Inc (IPIX)

[cabel]

If you look at the 200mg ITT population graph:

1) Moderate patients (grren line) started at 67.9% and ended at 25.0% or an improvement of 42.9%

2) Mild patients (purple line) started at 32.1% and ended at 17.9% or an improvement of 14.2%

Again given that it is a small patient pool,.. still the numbers are impressive,.. especially if you consider the Moderate patients ONLY.

If we had only MODERATE patients or even better, replace the MILD with SEVERE patients (which we are doing in Phase 2b),... we can logicially expect better overall results.

Add to that the fact we are upping the dose by 50% and 100% and going to the PASI standard of measurment instead of the IGA (which is more rigorous)

If we take the improvements in the Phase 2b trial:

1) increased dosage by 50% and 100%
2) PASI system instead of IGA
3) replace MILD with SEVERE patients

If those 3 improvments can help us at least hold the 42.9% improvement so that it actually is PASI75 improvement,... then we have easily beat Otezla because:

1) We act faster
2) We have much fewer side effects
3) We have a higher PASI75 of 42,9% to Otezla's PASI75 of 30%